Status:
COMPLETED
Physiologic Monitoring of Antidepressant Treatment Response
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Study Objectives: * to identify neurophysiologic effects of venlafaxine treatment in normal controls using quantitative EEG (QEEG) cordance * to examine the effects of venlafaxine on different rating...
Detailed Description
Pilot data suggest that in depressed patients treated with fluoxetine or venlafaxine, QEEG cordance detects changes of brain function within individual subjects as soon as two days after initiation of...
Eligibility Criteria
Inclusion
- All subjects will be between the ages of 18 - 65 and in good health (i.e., free of any medical condition known to affect brain function).
Exclusion
- All subjects will have no serious medical illness such as high blood pressure, heart disease, renal impairment, or cirrhosis of the liver. This will be assured by making sure that prospective subjects have had a normal physical exam with in one year prior to entry of the study.
- The investigators will also exclude subjects who meet DSM-IV axis I criteria for a mood, anxiety, cognitive, or psychotic disorder on the basis of a SCID-P interview, as well as those meeting criteria for cluster A or B axis II diagnoses.
- Subjects with a history of current or past active suicidal ideation or suicide attempts will be excluded from the study.
Key Trial Info
Start Date :
June 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2002
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00759317
Start Date
June 1 2001
End Date
September 1 2002
Last Update
July 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA Laboratory of Brain, Behavior, and Pharmacology
Los Angeles, California, United States, 90024